ATLANTA, May 23, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease treatments, announced today that it will present new results on its antiviral program to 'prevent' PML at an industry conference sponsored by the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, Roche and Biogen Idec). JC polyomavirus (JCV) is the causative agent of Progressive Multifocal Leukoencephalopathy (PML). IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, can clear JC polyomavirus (JCV) infection in at least some patients and is active against the form of the virus that infects the majority of human beings. The Company will present preliminary outcomes of its proposed treatment to 'prevent' PML. This oral medication, taken once or twice daily, is compatible with many different monoclonal antibody-based therapies and may offer a general solution to JCV infection as a companion therapeutic.
"JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression. The ability to clear JCV infection in at least some patients is encouraging. Further clinical evaluation confirming preliminary results is underway in several patient groups," said Milton H. Werner Ph.D., Chief Executive Officer and President of Inhibikase Therapeutics.
About Inhibikase Therapeutics
Founded in 2008, Inhibikase Therapeutics is a private biopharmaceutical company developing novel, small-molecule compounds to treat bacterial, viral, fungal and parasitic diseases through a common mechanism of action, often involving a single drug. Its pipeline of validated targets treat diseases therapeutically and prophylactically. By inhibiting human pathways used by multiple bacteria and viruses for reproduction in the patient, the Company's compounds resolve infection with a lower likelihood of stimulating resistance. Inhibikase Therapeutics is also developing a broad-spectrum antiviral specific for enveloped viruses, opening new avenues for vaccine development and biodefense. For more information, please visit the Company's website at www.inhibikase.com.
For Further Information Contact:
Milton H. Werner , PhD
President & CEO
Inhibikase Therapeutics, Inc.
(917) 494-0831 (m)
|SOURCE Inhibikase Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved